EP
NKTR icon

Essential Partners’s Nektar Therapeutics NKTR Stock Holding History

Essential Partners’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.19K Buy
+60
New +$4.39K ﹤0.01% 1621
2025
Q3 		– Sell
-3,732
Closed -$96.4K – 2747
2025
Q2 		$96.4K Buy
+3,732
New +$41.9K 0.04% 357

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Essential Partners's NKTR Position: Q2 2026 in Review

Essential Partners opened a new position in Nektar Therapeutics (NKTR) in Q2 2026: 60 shares worth $4.19K. The stake represents ﹤0.01% of the portfolio and ranks #1621 among its holdings. This is a return to the name: Essential Partners previously reported a position in NKTR as recently as Q2 2025.

Essential Partners first reported a position in NKTR in Q2 2025 and has held it in 2 quarters since. The position peaked at $96.4K in Q2 2025. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Essential Partners held 60 shares of Nektar Therapeutics worth $4.19K as of Q2 2026.
  • Nektar Therapeutics was a new Essential Partners position in Q2 2026.
  • Nektar Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1621 holding.
  • Essential Partners first reported a position in Nektar Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • Essential Partners's Nektar Therapeutics position peaked at $96.4K in Q2 2025.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.